123,305 Shares in Alphatec Holdings, Inc. (NASDAQ:ATEC) Bought by F M Investments LLC

F M Investments LLC purchased a new stake in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 123,305 shares of the medical technology company's stock, valued at approximately $1,132,000. F M Investments LLC owned about 0.09% of Alphatec as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in ATEC. Vanguard Group Inc. increased its position in shares of Alphatec by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 5,968,980 shares of the medical technology company's stock worth $54,795,000 after acquiring an additional 47,797 shares in the last quarter. American Century Companies Inc. grew its position in shares of Alphatec by 36.5% during the 4th quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company's stock valued at $45,800,000 after buying an additional 1,334,780 shares during the last quarter. State Street Corp boosted its position in Alphatec by 10.1% during the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company's stock valued at $17,453,000 after purchasing an additional 287,350 shares during the period. Geode Capital Management LLC grew its holdings in Alphatec by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 2,387,162 shares of the medical technology company's stock worth $21,919,000 after buying an additional 24,283 shares in the last quarter. Finally, Emerald Advisers LLC boosted its holdings in shares of Alphatec by 112.4% in the fourth quarter. Emerald Advisers LLC now owns 1,456,033 shares of the medical technology company's stock valued at $13,366,000 after acquiring an additional 770,586 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company's stock.

Insider Activity

In other news, EVP David Sponsel sold 12,946 shares of Alphatec stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $10.73, for a total transaction of $138,910.58. Following the sale, the executive vice president now owns 722,128 shares of the company's stock, valued at approximately $7,748,433.44. This trade represents a 1.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Patrick Miles sold 50,000 shares of the firm's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total value of $601,500.00. Following the completion of the transaction, the chief executive officer now directly owns 6,152,544 shares of the company's stock, valued at approximately $74,015,104.32. This trade represents a 0.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 278,800 shares of company stock valued at $3,201,469. 22.80% of the stock is owned by company insiders.

Alphatec Stock Performance

Shares of Alphatec stock traded up $0.19 on Thursday, reaching $10.42. The stock had a trading volume of 485,902 shares, compared to its average volume of 2,031,869. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The business's 50-day moving average price is $10.38 and its two-hundred day moving average price is $9.38. The stock has a market cap of $1.50 billion, a P/E ratio of -8.13 and a beta of 1.20. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $13.79.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The business had revenue of $176.79 million during the quarter, compared to analyst estimates of $172.74 million. On average, sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on ATEC shares. Barclays increased their price target on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, January 22nd. Needham & Company LLC restated a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research report on Thursday, February 27th. StockNews.com upgraded Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Alphatec in a report on Monday. Finally, Piper Sandler upped their price objective on shares of Alphatec from $12.00 to $13.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, Alphatec has an average rating of "Moderate Buy" and an average price target of $17.67.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.